TY - JOUR
AU - Etyang, Anthony O.
AU - Lucinde, Ruth K.
AU - Karanja, Henry
AU - Kalu, Catherine
AU - Mugo, Daisy
AU - Nyagwange, James
AU - Gitonga, John N.
AU - Tuju, James
AU - Wanjiku, Perpetual
AU - Karani, Angela
AU - Mutua, Shadrack
AU - Maroko, Hosea
AU - Nzomo, Eddy
AU - Maitha, Eric
AU - Kamuri, Evanson
AU - Kaugiria, Thuranira
AU - Weru, Justus
AU - Ochola, Lucy B.
AU - Kilimo, Nelson
AU - Charo, Sande
AU - Emukule, Namdala
AU - Moracha, Wycliffe
AU - Mukabi, David
AU - Okuku, Rosemary
AU - Ogutu, Monicah
AU - Angujo, Barrack
AU - Otiende, Mark
AU - Bottomley, Christian
AU - Otieno, Edward
AU - Ndwiga, Leonard
AU - Nyaguara, Amek
AU - Voller, Shirine
AU - Agoti, Charles N.
AU - Nokes, David James
AU - Ochola-Oyier, Lynette Isabella
AU - Aman, Rashid
AU - Amoth, Patrick
AU - Mwangangi, Mercy
AU - Kasera, Kadondi
AU - Ng’ang’a, Wangari
AU - Adetifa, Ifedayo
AU - Kagucia, E. Wangeci
AU - Gallagher, Katherine E.
AU - Uyoga, Sophie
AU - Tsofa, Benjamin
AU - Barasa, Edwine
AU - Bejon, Philip
AU - Scott, J. Anthony G.
AU - Agweyu, Ambrose
AU - Warimwe, George M.
PY - 2021
DA - April
TI - Seroprevalence of antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 among healthcare workers in Kenya
JO - Clinical Infectious Diseases
EP - 293
VL - 74
IS - 2
DO - https://doi.org/10.1093/cid/ciab346
AB - Background: Few studies have assessed the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Africa. We report findings from a survey among HCWs in 3 counties in Kenya. Methods: We recruited 684 HCWs from Kilifi (rural), Busia (rural), and Nairobi (urban) counties. The serosurvey was conducted between 30 July and 4 December 2020. We tested for immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay. Assay sensitivity and specificity were 92.7 (95% CI, 87.9-96.1) and 99.0% (95% CI, 98.1-99.5), respectively. We adjusted prevalence estimates, using bayesian modeling to account for assay performance. Results: The crude overall seroprevalence was 19.7% (135 of 684). After adjustment for assay performance, seroprevalence was 20.8% (95% credible interval, 17.5%–24.4%). Seroprevalence varied significantly (P &lt; .001) by site: 43.8% (95% credible interval, 35.8%–52.2%) in Nairobi, 12.6% (8.8%–17.1%) in Busia and 11.5% (7.2%–17.6%) in Kilifi. In a multivariable model controlling for age, sex, and site, professional cadre was not associated with differences in seroprevalence. Conclusion: These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.
PB - Oxford University Press
UR - https://eprints.gla.ac.uk/325335/
KW - Coronavirus (COVID-19)
ER